KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA RİSK FAKTÖRÜ OLAN HİPERHOMOSİSTEİNEMİ’NİN POLİKİSTİK OVER SENDROMUNDAKİ YERİ

Aim: Patients with Polycystic Ovary Syndrome (PCOS) are in the risk group at long-term for Cardiovascular System (CVS) related diseases due to hyperhomocysteinemia. Our study aims to investigate whether hyperhomocysteinemia can be used to determine the value of PCOS and a marker that can be used in the preliminary diagnosis of cardiovascular diseases. This study compares serum homocysteine levels between patients diagnosed with PCOS and healthy individuals. Material and Methods: Our study was a prospective cross-sectional study of 20-49 years old patients who applied to Reproductive Endocrinology Outpatient Clinics, 24 patients diagnosed with PCOS using Rotterdam criteria, and 26 healthy volunteer women as a control group. Anthropometric measurements of all participants included in the study were recorded. The blood samples of the individuals participating in the study were taken on the 2nd or 3rd day of menstruation following 12-hour fasting, centrifuged at -80 degrees, and serum homocysteine levels were measured by ELISA (Enzyme-Linked ImmunoSorbent Assay). Participants' serum homocysteine levels were divided into two groups as those below 30 μmol / L, and those above 30 μmol / L. Regardless of serum homocysteine levels, the participants were divided into groups that body mass index (BMIs) were higher, and lower than 25 kg (kilogram) / m2 (square meter), a waist circumference above, and below 80 cm (centimeter). Serum homocysteine levels of the created new groups were compared. Results: Serum homocysteine levels of women with PCOS were found higher than women without PCOS (p = 0.001). PCOS patients were significantly younger than the control group (p=0.017). No statistically significant difference was found between BMI, waist circumference, and serum homocysteine levels (p > 0.5). Conclusion: Regardless of the BMI, and waist circumference, screening routine serum homocysteine levels in young people with phenotype A PCOS, and treating patients with hyperhomocysteinemia may be useful in predicting, and preventing cardiovascular system relationship diseases that may develop in the long term.